Literature DB >> 10587585

Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy.

H Cao1, R A Hegele.   

Abstract

Patients with Dunnigan-type familial partial lipodystrophy (FPLD) are born with normal fat distribution, but after puberty experience regional and progressive adipocyte degeneration, often associated with profound insulin resistance and diabetes. Recently, the FPLD gene was mapped to chromosome 1q21-22, which harbours the LMNA gene encoding nuclear lamins A and C. Mutations in LMNA were shown to underlie autosomal dominant Emery-Dreifuss muscular dystrophy (EDMD-AD), which is characterized by regional and progressive skeletal muscle wasting and cardiac effects. We hypothesized that the analogy between the regional muscle wasting in EDMD-AD and the regional adipocyte degeneration in FPLD, in addition to its chromosomal localization, made LMNA a good candidate gene for FPLD. DNA sequencing of LMNA in five Canadian FPLD probands indicated that each had a novel missense mutation, R482Q, which co-segregated with the FPLD phenotype and was absent from 2000 normal alleles ( P = 1.1 x 10(-13)). This is the first report of a mutation underlying a degenerative disorder of adipose tissue and suggests that LMNA mutations could underlie other diseases characterized by tissue type- and anatomical site-specific cellular degeneration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10587585     DOI: 10.1093/hmg/9.1.109

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  158 in total

1.  A case of congenital generalized lipodystrophy: metabolic effects of four dietary regimens. Lack of association of CGL with polymorphism in the lamin A/C Gene.

Authors:  R Kazlauskaite; A T Santomauro; J Goldman; K Silver; S Snitker; B A Beamer; C J Yen; A R Shuldiner; B L Wajchenberg
Journal:  Clin Endocrinol (Oxf)       Date:  2001-03       Impact factor: 3.478

2.  Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice.

Authors:  O Gavrilova; B Marcus-Samuels; D Graham; J K Kim; G I Shulman; A L Castle; C Vinson; M Eckhaus; M L Reitman
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 3.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

Review 4.  Many roads lead to a broken heart: the genetics of dilated cardiomyopathy.

Authors:  J Schönberger; C E Seidman
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

Review 5.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

Review 6.  Protein farnesylation and disease.

Authors:  Giuseppe Novelli; Maria Rosaria D'Apice
Journal:  J Inherit Metab Dis       Date:  2012-02-04       Impact factor: 4.982

7.  Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARγ deficiency.

Authors:  Philippe M Campeau; Olga Astapova; Rebecca Martins; Jean Bergeron; Patrick Couture; Robert A Hegele; Todd Leff; Claude Gagné
Journal:  J Lipid Res       Date:  2012-07-02       Impact factor: 5.922

Review 8.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

9.  New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.

Authors:  Angelika Lüdtke; Janine Buettner; Hartmut H-J Schmidt; Howard J Worman
Journal:  J Med Genet       Date:  2007-09       Impact factor: 6.318

Review 10.  Genetics of insulin resistance.

Authors:  Maria M Mercado; John C McLenithan; Kristi D Silver; Alan R Shuldiner
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.